Hongwei Yao | Gastrointestinal Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Hongwei Yao | Gastrointestinal Pharmacology | Best Researcher Award

Prof. Hongwei Yao, capital medical university Affiliated Beijing Friendship Hospital, China

Prof. Dr. Hongwei Yao 🧑‍⚕️ is a renowned gastrointestinal surgeon with over 20 years of experience in diagnosing and treating GI tumors. 💉 He excels in laparoscopic and transanal endoscopic microsurgery (TEM) 🩺 and has led multiple research studies, authoring 100+ academic papers 📚—90+ focused on colorectal surgery. 🧬 He is the lead translator of Standard Laparoscopic Surgery for Upper GI Tract and co-translator of the national textbook Colorectal and Anal Surgery. 🔬 Prof. Yao holds two utility model patents for surgical innovations and continues to pioneer breakthroughs in colorectal cancer treatment. 🧠 His work bridges clinical expertise and cutting-edge research.

Publication Profile 

Orcid

Education

Prof. Dr. Hongwei Yao 🧑‍⚕️ is a distinguished gastrointestinal surgeon with over 20 years of clinical excellence in diagnosing and treating GI tumors 🧬. An expert in advanced surgical techniques such as laparoscopic surgery and transanal endoscopic microsurgery (TEM) 🔍, he is known for handling complex gastrointestinal procedures with precision. He has led numerous research projects and authored more than 100 academic papers 📚, with over 90 focusing on colorectal surgery. He served as lead translator of Standard Laparoscopic Surgery for Upper GI Tract 📘 and co-translator of Colorectal and Anal Surgery 📖. Prof. Yao also holds two utility model patents .

Editorial Appointments

Prof. Hongwei Yao 🧑‍⚕️ holds esteemed editorial roles in several leading medical journals. Since December 2019, he has served as Associate Editor for the Diseases of the Colon & Rectum journal 🧻, which is indexed in SSCI. Additionally, he has been a dedicated Editorial Board Member for the Chinese Journal of Inflammatory Bowel Diseases 💢 since February 2017, and for the Chinese Journal of Digestive Surgery 🩺 since July 2021, both indexed in CSCD and CSTPCD. These appointments reflect his profound expertise in gastrointestinal surgery and commitment to advancing medical research and literature 📚.

Research Focus

Prof. Hongwei Yao 🧑‍⚕️ focuses his groundbreaking research on colorectal cancer, gastrointestinal surgery, and translational oncology 🧬. His core interest lies in neoadjuvant therapies combining chemoradiation with immunotherapy (especially PD-1/PD-L1 blockade) for treating locally advanced rectal cancer 🎯. His innovative studies explore gut microbiota, nanomedicine, biospectroscopy, and surgical optimization to personalize cancer care 🧪. He also advances wound healing and stem cell therapies for post-surgical recovery 🩹. Through high-impact publications and clinical trials, Prof. Yao contributes to redefining standards in cancer diagnostics, surgical margins, and immune modulation in GI tumors ⚕️.

Publication Top Notes

Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial

Opportunities and challenges of indocyanine green in gastrointestinal cancers for intraoperative and nano-medicine application

Opportunities and challenges of nanomaterials in wound healing: Advances, mechanisms, and perspectives

Enhancing thromboprophylaxis after colorectal cancer surgery in China: Bridging the gap between evidence and implementation through pathway optimization

Exploring causal correlations between circulating levels of cytokines and colorectal cancer risk: A Mendelian randomization analysis

Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer

Definition and grading of anastomotic leakage following right hemicolectomy

Perfusion outcomes with near-infrared indocyanine green imaging system in laparoscopic total mesorectal excision for mid-rectal or low-rectal cancer (POSTER): a study protocol

The Role and Prospects of Mesenchymal Stem Cells in Skin Repair and Regeneration

Shuwei Zhou | Gastrointestinal Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Shuwei Zhou | Gastrointestinal Pharmacology | Best Researcher Award

Ms. Shuwei Zhou, Southeast University Zhongda Hospital, China

🔬 Dr. Shuwei Zhou is a distinguished researcher specializing in imaging and nuclear medicine at Zhongda Hospital, Southeast University, China. 🏥 She holds a Ph.D. in Imaging and Nuclear Medicine from Southeast University and a B.A. & Master’s from Hunan University of Chinese Medicine. 🎓 Dr. Zhou has authored numerous high-impact SCI publications 📑 focusing on HCC, LI-RADS, MRI diagnostics, and treatment response. Her contributions include 4 national research projects and 2 patents. 🏆 As a leading expert in radiology and medical imaging, her work advances diagnostic accuracy and patient care in oncology and musculoskeletal disorders. ⚕️✨

Publication Profile

Scopus

Education

Ms. Shuwei Zhou 🎓 has showcased outstanding academic excellence, earning a Ph.D. in Imaging and Nuclear Medicine from the School of Medicine at Southeast University 🏥. Her strong foundation in the field began at Hunan University of Chinese Medicine, where she completed her B.A. and Master’s degree, ranking 1st out of 159 students 🏆. With expertise in molecular and functional imaging, interventional radiology, and pathology 🔬, she has developed a deep understanding of advanced medical diagnostics. Her dedication to research and innovation continues to shape the future of nuclear medicine and imaging technology. 🚀

Experience 

Ms. Shuwei Zhou 🔬 has made significant research contributions, publishing in esteemed journals like the American Journal of Roentgenology, Abdominal Radiology, and Frontiers in Immunology 📚. As the first author, she has led groundbreaking studies on MRI contrast agents, diagnostic performance, and treatment response in hepatocellular carcinoma (HCC) 🏥. Her interdisciplinary expertise extends to osteoporosis prediction, the role of gut microbiota in inflammatory bowel disease, and dual-energy CT for bone mineral density 🦴. Through her innovative research, she continues to advance medical imaging and diagnostic precision, making a lasting impact on the field of nuclear medicine. 🚀

Awards

Ms. Shuwei Zhou 🎓 is a distinguished researcher whose impressive portfolio includes first-author contributions in high-impact journals, leadership in scientific projects, and remarkable interdisciplinary expertise 🔬. Her groundbreaking work in imaging and nuclear medicine, particularly in hepatocellular carcinoma research and diagnostic imaging techniques 🏥, has significantly advanced the field. With a strong commitment to innovation and precision in medical diagnostics, she continues to push the boundaries of research. Her achievements make her a highly deserving candidate for the Best Researcher Award 🏆, recognizing her invaluable contributions to the future of medical imaging and nuclear medicine. 🚀

Research Focus

Shuwei Zhou’s research primarily focuses on medical imaging 🏥📡 and oncology, with a particular emphasis on hepatocellular carcinoma (HCC) 🏨🧬 and non-radiation treatment response assessment. She is actively involved in the development of diagnostic algorithms 📊🔍, such as the LI-RADS Nonradiation Treatment Response Algorithm, and predictive models like the TRACE Model, which help evaluate the effectiveness of transarterial chemoembolization (TACE) 💉⚕️ in patients with unresectable liver cancer. Her contributions aim to enhance precision medicine 🎯 and optimize clinical decision-making for better patient outcomes.

Publication Top Notes

LI-RADS Nonradiation Treatment Response Algorithm Version 2024: Diagnostic Performance and Impact of Ancillary Features

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma

Mifleh Tatour | Gastrointestinal Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Mifleh Tatour | Gastrointestinal Pharmacology | Best Researcher Award

Dr. Mifleh Tatour, Clalit Health Services, Israel

Dr. Mifleh Tatour (b. 1989, Israel) is a distinguished physician and researcher specializing in family medicine and hematology. He earned his M.D. from the Technion – Israel Institute of Technology and holds an M.Sc. in Hematology and Cancer. A prolific researcher, he has published extensively on autoimmune hepatitis and heparanase activity. Currently, he serves as a family medicine resident at Clalit Health Services and a lecturer at Bar-Ilan University. Passionate about medical education, he mentors aspiring physicians. Fluent in Hebrew and Arabic, Dr. Tatour is committed to advancing healthcare and medical training. 🏥🔬

Publication Profile

Education

Dr. Mifleh Tatour 🎓 is a distinguished medical professional with a strong background in hematology, cancer research, and hepatology. He earned his B.Sc. (Cum Laude) in Medical Laboratory Sciences (2008-2012) and an M.Sc. (Cum Laude) in Hematology and Cancer (2013-2015) from the Technion – Israel Institute of Technology 🏥. He later completed his M.D. (2014-2019) at the same institution. Dr. Tatour has contributed to multiple high-impact publications, including studies on autoimmune hepatitis and heparanase activity. In 2024, he was accepted into the prestigious “Northern Stars” program 🌟 at Bar-Ilan University. His research continues to shape the future of hepatology and oncology.

Work Experience

Dr. Mifleh Tatour 🩺 is an accomplished medical educator and family medicine specialist. Since 2021, he has been a Family Medicine Resident at Clalit Health Services – Northern District, while also serving as a lecturer and instructor at Bar-Ilan University’s Faculty of Medicine 🎓. He directs the “Bread and Butter” course for first-year residents and mentors students in various programs. Previously, he worked at Emek Medical Center and Carmel Medical Center. Passionate about education, he has trained students in hematology, psychometrics, and medical school preparation 📚. His dedication to teaching and mentoring continues to shape future healthcare professionals.

Clinical Impact

Dr. Mifleh Tatour 🏥 is a dedicated Family Medicine Resident at Clalit Health Services, seamlessly integrating clinical practice, research, and education. With experience as a physician assistant, internal medicine instructor, and hematology lab instructor, he has developed a comprehensive medical expertise 🩺. His commitment to patient care is complemented by his passion for teaching, mentoring future doctors, and advancing medical knowledge 📚. Through his roles in academia and clinical settings, Dr. Tatour continues to make a significant impact on healthcare, ensuring high-quality treatment while shaping the next generation of physicians 👨‍⚕️.

Research Focus

Dr. Mifleh Tatour’s research primarily focuses on the intersection of autoimmune diseases 🦠 and hematological malignancies 🧬, particularly the increased risk of Non-Hodgkin Lymphoma (NHL) in patients with Autoimmune Hepatitis (AIH) 🏥. His work involves large-scale retrospective cohort studies 📊 to identify potential pathophysiological links 🔬 between chronic liver inflammation and lymphoproliferative disorders. His research aims to improve early detection 🛑 and risk assessment ⚠️ for AIH patients susceptible to lymphoma, contributing to personalized medicine 🏥 and better clinical outcomes 📈. His work is significant in the fields of gastroenterology, immunology, and oncology 🩺.

Publication Top Notes

Increased Risk of Non-Hodgkin Lymphoma in Autoimmune Hepatitis: A Large Retrospective Cohort Study